HC
NVO

Hourglass Capital’s Novo Nordisk NVO Stock Holding History

Hourglass Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,700
Closed -$316K – 116
2025
Q3 		$316K Sell
5,700
-17,430
-75% -$1.02M 0.07% 95
2025
Q2 		$1.6M Buy
23,130
+2,310
+11% +$157K 0.39% 68
2025
Q1 		$1.45M Buy
20,820
+1,870
+10% +$154K 0.38% 71
2024
Q4 		$1.63M Buy
18,950
+3,330
+21% +$360K 0.45% 65
2024
Q3 		$1.86M Buy
15,620
+140
+0.9% +$18.7K 0.52% 56
2024
Q2 		$2.21M Sell
15,480
-360
-2% -$47.7K 0.66% 52
2024
Q1 		$2.03M Buy
15,840
+700
+5% +$83.3K 0.61% 52
2023
Q4 		$1.57M Buy
15,140
+1,600
+12% +$158K 0.5% 56
2023
Q3 		$1.23M Sell
13,540
-300
-2% -$26.4K 0.43% 62
2023
Q2 		$1.12M Buy
+13,840
New +$1.13M 0.39% 65

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hourglass Capital's NVO Position: Q4 2025 in Review

Hourglass Capital sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 5,700 shares — an estimated $316K sold.

Hourglass Capital first reported a position in NVO in Q2 2023 and held it in 10 quarters. The position peaked at $2.21M in Q2 2024. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Hourglass Capital reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Hourglass Capital sold 5,700 Novo Nordisk shares in Q4 2025, an estimated $316K.
  • Hourglass Capital first reported a position in Novo Nordisk in Q2 2023 and held it in 10 quarters.
  • Hourglass Capital's Novo Nordisk position peaked at $2.21M in Q2 2024.
  • 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Hourglass Capital's 13F filing for Q4 2025, filed 14 Jan 2026.